Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
 over alleged Violations of Securities Laws announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Nov. 29, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in California on behalf of certain purchasers of shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) over alleged Securities Laws Violations by Ligand Pharmaceuticals Inc.
Investors who purchased shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) have certain options and for certain investors there are short and strict deadlines running. Deadline: January 17, 2017. NASDAQ: LGND investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that Ligand Pharmaceuticals Inc. overstated the value of certain Deferred Tax Assets by approximately $27.5 million or 13%, that Ligand Pharmaceuticals Inc.’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015, that Ligand Pharmaceuticals Inc. did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions, that in turn, Ligand Pharmaceuticals Inc. lacked effective internal control over financial reporting, and that as a result, defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On November 9, 2016, Ligand Pharmaceuticals Inc. announced that it would not be able to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 and that it was reviewing a potential restatement.
On November 14, 2016, Ligand Pharmaceuticals Inc. announced that it would restate financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error. Ligand Pharmaceuticals Inc. also disclosed that its management determined that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions.
Those who purchased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
